Class | Name/Company | Approval Dates and Comments |
Antipsoriatic Agent |
Immunex/Wyeth-Ayerst Laboratories | The US FDA gave priority review status to this tumor-necrosis-factor |
Antibacterial Agent |
BenzaClin™ | The US FDA approved a labeling change in September 2001, for |
Oral Contraceptive |
Pfizer | The US FDA approved an additional indication for this oral |
Antihistamine |
Schering-Plough | The European Commission of the European Union granted marketing |
Enzyme Replacement Therapy |
| The Norwegian Medicines Agency granted marketing authorization |
Antibacterial Agent |
Geneva Pharmaceuticals | The US FDA tentatively approved an ANDA in August 2001, for |
Antifungal Agent |
| The US FDA approved a new indication in August 2001, for this |
Drug News | |
Public Health Advisory | The US FDA is approving new labeling for the use of several antibiotics to treat anthrax. The use of this and |
Anti-acne Agent | Pilot Therapeutics signed an agreement with Bristol-Myers Squibb (BMS) giving Pilot exclusive, worldwide |
Corticosteroids | Connetics Corporation announced in October 2001, that it has made available 50gm cans of its topical |